ArticlePloS one2025
Economics of vaccination against diarrhoea and respiratory diseases in French cow calves' systems: A modelling approach.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess the economic benefits of vaccination against diarrhoea and respiratory diseases in cow-calf systems, a stochastic mechanistic mathematical programming bio-economic model was developed for a beef Charolais breed farm. The model reproduced herd dynamics on a weekly basis over a 10-year period, including animal growth, reproduction and diseases risks and control (treatments and vaccination). Three baseline risk levels of diarrhoea and respiratory disease were considered to simulate low, average, and high infection risks on the farm. The results demonstrated the model's ability to reproduce average farm dynamics, with diarrhoea prevalence ranging from 8% to 33% and respiratory diseases from 13% to 79%. On average, prevalences were decreased by 24% and 50%, respectively, due to vaccination, which also reduced the 2-day to 1-month mortality rates by 2-3% and 15-17%, respectively. The net value of vaccination was positive except in cases of low infection risk of diarrhoea and respiratory diseases: the return on investment (ROI) of vaccination was 0.4-0.5 (€1 invested yields €0.4-0.5) in the baseline scenario (middle infection risks), negative under low infection risks, and reached 1 (€1 invested yields €1) for high infection risks. The results also showed that farmers may earn €58-75 in additional revenue per extra hour of labour dedicated to vaccination in the medium-risk scenario. Despite the limited availability of data for cow-calf systems, this study demonstrated the economic benefit of vaccination in most combinations of scenarios and risks. The profitability of vaccination was challenged when low disease risks were considered, but in such cases, vaccination may serve as insurance against financial losses in case of health status deterioration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.